Peptide Tools to Study EBV
About EBV (Epstein-Barr Virus)
Epstein-Barr virus (EBV or HHV-4) belongs to the family of Herpesviridae and is known as the cause of infectious mononucleosis. Being able to establish a long-term, latent infection in human B cells, it is prevalent in the adult population (worldwide 90%).
EBV is associated with a range of human diseases and cancers:
- Hodgkin’s and Burkitt’s lymphoma
- Nasopharyngal carcinoma
- Main cause of post-transplant lymphoproliferative disease (PTLD) in immune suppressed transplant patients
- Increases the risk of certain autoimmune diseases, e.g. lupus erythematosus, rheumatoid arthritis and multiple sclerosis
- Plays a role in the development of chronic fatigue syndrome (CFS)
The latent EBV Antigens
During latent infection EBV expresses a small number of genes (e.g. EBNA1 -3 and LMP1 -2). Three major types of latency can be differentiated by their distinct expression patterns and are associated with the various types of diseases and cancer. Both, humoral and cellular (mainly CTL) immune responses play a role in controlling the primary and the latent phases of EBV infection.
JPT's Peptide Tools to Study EBV (Epstein-Barr Virus):
Cellular Immune Response Profiling
PepMix™ Peptide Pools for antigen specific stimulation of T-cells in
- Immune monitoring of high-risk patients
- Qualification of immunodominant antigens
- Validating clinical T-cell assays
PepMix™ Collection EBV
The PepMix™ Collection EBV provides peptide pools (2 aliquots each) of 13 immunodominant antigens in one plate for fast and economic immune response profiling.
EBV PepMix™ Peptide Pools
Individual peptide pools comprise overlapping peptide scans through single immunodominant antigens:
BARF1, BMLF1, BMRF1, BRLF1, BZLF1, EBNA-LP, EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, LMP1, LMP2, GP350/340
Tailored EBV PepMix™ Peptide Pools
Peptide Pools tailored for your specific needs!
Humoral Immune Response Profiling
Peptide Microarrays for humoral immune response profiling in
- Immune monitoring of humoral responses
- Profiling of EBV specific samples or antibodies
- Evaluation of co-infection
- Detection of epitopes and epitope spreading
Catalog RepliTope™ Peptide Microarrays
Ready-made peptide microarrays displaying overlapping peptides through single immunodominant antigens: BARF1, BMLF1, BMRF1, BRLF1, BZLF1, EBNA-LP, EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, LMP1, LMP2, GP350/340.
Catalog RepliTope™ Antigen Collection
The RepliTope™ Antigen Collection combines overlapping peptides for all the proteins above on one microarray for optimal coverage of the most important antigens in a single experiment.
> RepliTope™ Peptide Microarrays Product Page
Tailored PepStar™ Peptide Microarrays
You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored peptide microarray.
> PepStar™ Peptide Microarrays Product Page
Our tailored Peptide ELISA plates are offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays.
GxP Peptides & Pools
GxP Peptides & Pools
We established an enhanced production environment for GxP peptides that goes beyond ISO 9001:2015 regulations for the more stringent product requirements of immunotherapy as well as vaccine & drug development. Thus, the resulting GxP peptides and GxP peptide pools have been approved for specific clinical applications.
Selected EBV Related References
"Identification of GLA/SE as an Effective Adjuvant for the Induction of Robust Humoral and Cell-mediated Immune Responses to EBV-gp350 in Mice and Rabbits"
Heeke et al., Vaccine (2016) – PMID: 27085175
"Epstein-Barr Virus Reactivation Does Not Impact Total T-Cell Reconstitution But Is Associated With Decreased Functional T Cells after Stem Cell Transplantation"
Pietersma et al., J Clin Cell Immunol (2015)
"T Cells Specific for Different Latent and Lytic Viral Proteins Efficiently Control Epstein-Barr Virus–Transformed B Cells"
Nowakowska et al., Cytotherapy (2015) – PMID: 26276009
"Selection of Adenovirus-specific and Epstein-Barr virus–specific T Cells With Major Histocompatibility Class I Streptamers Under Good Manufacturing Practice (GMP)–Compliant Conditions"
Freimüller et al., Cytotherapy (2015) – PMID: 25866178
"High-density Preculture of PBMCs Restores Defective Sensitivity of Circulating CD8 T Cells to Virus- and Tumor-derived Antigens"
Wegner et al., Blood (2015) – PMID: 26024876
"Early Exposure to Interleukin-21 Limits Rapidly Generated Anti–Epstein-Barr Virus T-cell Line Differentiation"
Orio eta l., Cytotherapy. (2015) – PMID: 25661862
"A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein-Barr virus (EBV) Target Antigens: a Phase I Trial in UK Patients with EBV-positive Cancer"
Taylor et al., Clinical Cancer Research (2014) - PMID: 25124688
"Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections After HSCT "
Papadopoulou et al., Sci Transl Med. (2014) - PMID: 24964991
"Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome"
Loebl et al., PLOS ONE (2014) - PMID: 24454857
Selected EBV Related Testimonials
"My group is developing therapeutic strategies for using in vitro expanded virus-specific T cells (VSTs) for the treatment of viral infections in immunocompromised patients. We recently demonstrated the feasibility and clinical benefit associated with the infusion of rapidly generated single-culture VSTs, manufactured using JPT's GxP PepMix™ peptide pools covering 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BK, and HHV6). When administered to 11 allogeneic stem cell transplant recipients, 8 of whom had up to four active infections, these VSTs produced an overall 94% response rate."
Ann Leen, PhD, Baylor College of Medicine, Houston, TX, USA
"The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses we have a permanent need for peptides and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving it's peptide based services."
Prof. Dr. Carmen Scheibenbogen, Charité Berlin, Germany
Selected EBV Related Application Notes
Peptide-stimulated expansion of virus-specific T cells for preventative treatment after allogeneic stem cell transplantation
Gary et. al, Apllication Note (2015)
Multiple Sclerosis and Epstein‐Barr Virus Infection - An Epitope Mapping Study
Reimer et al., Application Note (2014)
BioTides™ as High Throughput Screening Tool for the Identification of Antibody Binding Sites
Kuehne et al., Application Note (2012)
A Modular Approach for Epitope Discovery and High-Resolution Profiling of Humoral Immune Responses
Pawlowski et al., Application Note (2013)
PepMix™ Peptide Pools for Clinical Applications
Keirnan et al., Application Note (2012)
More application notes
Performance Control of T-cell Assays
Check the innovative, easy method to produce cellular reference samples for antigen-specific T-cell assays (TERS).
Analyze 21 Samples on a Single Microarray with our new RepliTope™ Multiwell Microarrays available for Tumor Antigens and Infections